BRPI0811499B8 - métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral. - Google Patents

métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.

Info

Publication number
BRPI0811499B8
BRPI0811499B8 BRPI0811499A BRPI0811499A BRPI0811499B8 BR PI0811499 B8 BRPI0811499 B8 BR PI0811499B8 BR PI0811499 A BRPI0811499 A BR PI0811499A BR PI0811499 A BRPI0811499 A BR PI0811499A BR PI0811499 B8 BRPI0811499 B8 BR PI0811499B8
Authority
BR
Brazil
Prior art keywords
virus
viral antigen
purifying
preparing
methods
Prior art date
Application number
BRPI0811499A
Other languages
English (en)
Inventor
Mitterer Artur
Schafhauser Horst
Grillberger Leopold
Reiter Manfred
Mundt Wolfgang
Original Assignee
Baxalta GmbH
Baxalta Inc
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39596388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0811499(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxalta GmbH, Baxalta Inc, Baxter Healthcare Sa, Baxter Int filed Critical Baxalta GmbH
Publication of BRPI0811499A2 publication Critical patent/BRPI0811499A2/pt
Publication of BRPI0811499B1 publication Critical patent/BRPI0811499B1/pt
Publication of BRPI0811499B8 publication Critical patent/BRPI0811499B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C12N2760/16252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Physics & Mathematics (AREA)

Abstract

métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral a presente invenção fornece um método para a purificação de um vírus ou antígeno viral que compreende fornecer uma preparação viral e centrifugação da dita preparação viral em um gradiente de um açúcar estabelecido pela adição de duas ou mais camadas de açúcar tamponadas de concentração diferente. o método leva a rendimentos mais altos e reduz a agregação não desejada do vírus ou antígeno viral pelo aumento do volume do grupo de pico.
BRPI0811499A 2007-05-04 2008-04-30 métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral. BRPI0811499B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92769207P 2007-05-04 2007-05-04
US60/927692 2007-05-04
PCT/EP2008/003531 WO2008135229A2 (en) 2007-05-04 2008-04-30 Formulation of sugar solutions for continuous ultracentrifugation for virus purification

Publications (3)

Publication Number Publication Date
BRPI0811499A2 BRPI0811499A2 (pt) 2014-10-14
BRPI0811499B1 BRPI0811499B1 (pt) 2019-06-04
BRPI0811499B8 true BRPI0811499B8 (pt) 2021-05-25

Family

ID=39596388

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811499A BRPI0811499B8 (pt) 2007-05-04 2008-04-30 métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.

Country Status (18)

Country Link
US (4) US8969533B2 (pt)
EP (1) EP2155864B1 (pt)
JP (2) JP5745717B2 (pt)
KR (4) KR101873891B1 (pt)
CN (2) CN101688187A (pt)
AR (1) AR066449A1 (pt)
AU (1) AU2008248904B2 (pt)
BR (1) BRPI0811499B8 (pt)
CA (1) CA2687119C (pt)
CL (1) CL2008001294A1 (pt)
HK (1) HK1211320A1 (pt)
IL (1) IL201898A (pt)
MX (1) MX2009011897A (pt)
PE (1) PE20090284A1 (pt)
RU (1) RU2503719C2 (pt)
TW (1) TWI472620B (pt)
WO (1) WO2008135229A2 (pt)
ZA (1) ZA200907743B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969533B2 (en) * 2007-05-04 2015-03-03 Baxter International Inc. Formulation of sugar solutions for continuous ultracentrifugation for virus purification
CA2750055A1 (en) 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Method for purifying viruses using a density gradient
JP2013523175A (ja) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
CN101948813B (zh) * 2010-09-04 2012-07-25 国家海洋局第一海洋研究所 一种刺参球形病毒的分离方法
BE1023903B1 (fr) 2014-12-16 2017-09-08 Glaxosmithkline Biologicals Sa Nouveau procédé
EP3255054A1 (en) * 2016-06-06 2017-12-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the purification of biological macromolecular complexes
CN110168081B (zh) * 2016-11-04 2024-08-16 武田药品工业株式会社 腺相关病毒纯化方法
SG11201908055WA (en) 2017-03-03 2019-09-27 Baxalta Inc Methods for determining potency of adeno-associated virus preparations
CN112198318B (zh) * 2020-07-15 2021-07-20 南京岚煜生物科技有限公司 抗体标准品赋值和抗体检测试剂最低检出限确定的方法
WO2022229702A2 (en) 2021-04-30 2022-11-03 Takeda Pharmaceutical Company, Ltd. Aav8 capsid variants with enhanced liver targeting
WO2022229703A2 (en) 2021-04-30 2022-11-03 Takeda Pharmaceutical Company, Ltd. New aav8 based immune escaping variants
CA3234817A1 (en) * 2021-10-12 2023-04-20 Remo MOOMIAIE Systems and methods for manufacturing of therapeutic cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
US4217418A (en) * 1978-05-08 1980-08-12 Merck & Co., Inc. Recovery of small particles by flow centrifugation
DE2964132D1 (en) 1978-05-08 1983-01-05 Merck & Co Inc A process for the direct extraction of small size particles of up to 50 nm from a protein aceous liquid
JPH06247995A (ja) * 1991-06-24 1994-09-06 Asahi Chem Ind Co Ltd 新規なシアリル（α２−６）ラクトテトラオシルセラミド
RU2080124C1 (ru) * 1995-10-19 1997-05-27 Санкт-Петербургский научно-исследовательский институт вакцин и сывороток Способ получения живой гриппозной вакцины
ES2543630T3 (es) * 2003-04-01 2015-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos dirigidos contra el complejo E1E2 del virus de la hepatitis C y sus epítopos
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
CN1739801A (zh) * 2004-08-27 2006-03-01 上海生物制品研究所 一种流行性感冒病毒裂解疫苗及其制备方法
US8969533B2 (en) * 2007-05-04 2015-03-03 Baxter International Inc. Formulation of sugar solutions for continuous ultracentrifugation for virus purification

Also Published As

Publication number Publication date
JP5745717B2 (ja) 2015-07-08
CA2687119C (en) 2021-06-08
CN101688187A (zh) 2010-03-31
RU2009144980A (ru) 2011-06-10
JP6031082B2 (ja) 2016-11-24
CL2008001294A1 (es) 2009-03-06
JP2015061538A (ja) 2015-04-02
MX2009011897A (es) 2010-02-04
KR101998537B1 (ko) 2019-07-09
US20080274138A1 (en) 2008-11-06
US9732327B2 (en) 2017-08-15
AR066449A1 (es) 2009-08-19
CN104694489A (zh) 2015-06-10
HK1211320A1 (en) 2016-05-20
EP2155864A2 (en) 2010-02-24
IL201898A (en) 2013-11-28
KR20150082676A (ko) 2015-07-15
PE20090284A1 (es) 2009-03-17
KR101744430B1 (ko) 2017-06-20
KR101873891B1 (ko) 2018-07-04
EP2155864B1 (en) 2013-07-17
US20170369853A1 (en) 2017-12-28
AU2008248904A1 (en) 2008-11-13
TW200914615A (en) 2009-04-01
AU2008248904B2 (en) 2014-10-09
KR20180077305A (ko) 2018-07-06
CA2687119A1 (en) 2008-11-13
IL201898A0 (en) 2011-08-01
TWI472620B (zh) 2015-02-11
HK1138318A1 (en) 2010-08-20
BRPI0811499B1 (pt) 2019-06-04
WO2008135229A3 (en) 2008-12-31
US20160060603A1 (en) 2016-03-03
BRPI0811499A2 (pt) 2014-10-14
KR20100017594A (ko) 2010-02-16
WO2008135229A2 (en) 2008-11-13
RU2503719C2 (ru) 2014-01-10
US8969533B2 (en) 2015-03-03
JP2010525798A (ja) 2010-07-29
ZA200907743B (en) 2010-09-29
KR20170065671A (ko) 2017-06-13
US20100239609A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
Saleh et al. Vaccine development throughout history
MX2009011897A (es) Formulacion de soluciones de azucar para la ultracentrifugacion continua para la purificacion de virus.
WO2013068563A3 (en) Antibody molecules having specificity for human ox40
BR112018013218A2 (pt) derivado de acrilanilida, método de preparação e aplicação do mesmo na farmácia
WO2010096418A3 (en) Antibody molecules having specificity for human ox40
AR073959A1 (es) Vacuna de combinacion con tos ferina acelular y metodo para su elaboracion
EP2670443A4 (en) FOR NUCLEIC ACID MOLECULAR ENCODING NEW HERPES ANTIGENES, VACCINES THEREOF AND METHOD OF USE THEREOF
BR112013011194A2 (pt) partículas de glicoproteína semelhantes a vírus (vlps) da raiva.
MY202109A (en) Viral replication inhibitors
JP2013537518A5 (pt)
WO2009121004A3 (en) Neutralizing molecules to viral antigens
RU2014104090A (ru) Липосомы с эффективным соотношением n:p для доставки молекул phk
UA118010C2 (uk) Інгібітори реплікації вірусів грипу
BR112013005427A2 (pt) composição imunogênica, vacina, método para tratamento ou prevenção de doença, e para preparar a composição imunogênica ou vacina, uso da vacina,e, composição farmacêutica.
MX2014000753A (es) Procedimiento para producir antigeno viral y vacunas.
BRPI0520330A2 (pt) adjuvante a base de ácido polinosìnico-policitidìlico
WO2012014078A3 (en) Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy
BR112015012711A2 (pt) método de produção de uma vacina de mycoplasma
BR112012016048A2 (pt) "exossomas derivados de reticulócitos infectados com plasmodium sp., método para obter os mesmos e usos dos mesmos".
BR112015008418A2 (pt) uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae
WO2011156710A3 (en) Combination therapy with lisdexamphetamine and extended release guanfacine
BR112018012237A2 (pt) conjugados oligonucleotídeos-peptídeos
BRPI0822069B8 (pt) método para preparação de um extrato de fruta de cardo leiteiro
BR112014015112A2 (pt) inibidores de sialoadesina para o tratamento de doenças causadas por vírus encapsulado
BR112017003167A2 (pt) método in vitro e aparelho para análise do comportamento de substâncias em ambiente fisiológico simulado

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAXALTA GMBH (CH) , BAXALTA INCORPORATED (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)